Oncologist最新文献

{"title":"Prediction of methotrexate neurotoxicity using clinical, sociodemographic, and area-based information in children with acute lymphoblastic leukemia.","authors":"Rachel D Harris, Olga A Taylor, Maria Monica Gramatges, Amy E Hughes, Mark Zobeck, Sandi Pruitt, M Brooke Bernhardt, Ashley Chavana, Van Huynh, Kathleen Ludwig, Laura Klesse, Kenneth Heym, Timothy Griffin, Rodrigo Erana, Juan Carlos Bernini, Ashley Choi, Yuu Ohno, Melissa A Richard, Alanna C Morrison, Han Chen, Bing Yu, Philip J Lupo, Karen R Rabin, Michael E Scheurer, Austin L Brown","doi":"10.1093/oncolo/oyaf055","DOIUrl":"10.1093/oncolo/oyaf055","url":null,"abstract":"<p><strong>Background: </strong>Methotrexate is a critical component of pediatric acute lymphoblastic leukemia (ALL) therapy that can result in neurotoxicity which has been associated with an increased risk of relapse. We leveraged machine learning to develop a neurotoxicity risk prediction model in a diverse cohort of children with ALL.</p><p><strong>Methods: </strong>We included children (age 2-20 years) diagnosed with ALL (2005-2019) and treated in Texas without pre-existing neurologic disease. Clinical information was obtained by medical record review. Neurotoxicity occurring post-induction and prior to maintenance therapy was defined as neurologic episodes occurring within 21 days of methotrexate. Suspected cases were independently confirmed by 2 pediatric oncologists. Demographic and clinical factors were compared using logistic regression. The dataset was randomly split (80/20) for training and testing. random forest (RF) with boosting and downsampling using 5-repeat, 10-fold cross-validation was used to construct a predictive model.</p><p><strong>Results: </strong>Neurotoxicity developed in 115 (8.7%) of 1325 eligible patients. Several factors including older age at diagnosis (OR = 1.19, 95% CI: 1.15-1.24) and Latino ethnicity (OR = 2.79, 95% CI: 1.83-4.35) were associated with neurotoxicity. The RF had an area under the curve of 0.77 with a train error rate of 0.29 and a test error rate of 0.24. The overall sensitivity was 0.73, and specificity was 0.69.</p><p><strong>Conclusions: </strong>In one of the largest studies of its kind, we developed a novel risk prediction model of methotrexate-related neurotoxicity. Ultimately, a validated model may help guide the development of personalized treatment strategies to reduce the burden of neurotoxicity in children diagnosed with ALL.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":"30 6","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12205976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highlights of American Society of Hematology 2024-lymphoma.","authors":"Alexander D Sanjurjo, Barbara Pro, Hua-Jay J Cherng","doi":"10.1093/oncolo/oyaf166","DOIUrl":"10.1093/oncolo/oyaf166","url":null,"abstract":"","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12207876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144267930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"KRAS mutated NSCLC: past, present, and future directions in a rapidly evolving landscape.","authors":"Austin Frisch, Eric Martin, So Yeon Kim, Jonathan W Riess, Triparna Sen, Nagla Karim","doi":"10.1093/oncolo/oyaf153","DOIUrl":"10.1093/oncolo/oyaf153","url":null,"abstract":"<p><p>Non-small cell lung cancer (NSCLC) is among one of the most common and deadliest malignancies worldwide. With this new era of precision medicine, oncogenic driver genes and immunotherapy have changed the way we classify and treat this disease. Among these genes, the Kirsten rat sarcoma virus (KRAS) gene is the most mutated in NSCLC and has been the focus of numerous clinical trials for targeted therapy over the past few years. Here, we present an in-depth literature review of past, present, and future KRAS mutated NSCLC treatment with KRAS inhibitor monotherapy and combinatorial approaches including immunotherapy. The molecular biology behind KRAS targeted therapy is discussed while highlighting the difficulties of KRAS inhibitor treatment, including resistance, and the next steps needed to overcome them.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":"30 6","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12207871/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase I trial of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors.","authors":"Yu Jiang, Xu Liang, Mei-Li Sun, Ge Gao, Yi Gong, Hui-Ping Li, Jie Liu, Yong-Sheng Wang","doi":"10.1093/oncolo/oyaf077","DOIUrl":"10.1093/oncolo/oyaf077","url":null,"abstract":"<p><strong>Background: </strong>Preclinical models demonstrated promising anti-tumor activity of SPH4336, a novel oral, highly selective cyclin-dependent kinase (CDK) 4/6 inhibitor.</p><p><strong>Methods: </strong>This phase I study enrolled patients who received SPH4336 orally in 6 dose-escalation cohorts (50-600 mg) in a 3 + 3 design. Based on tolerability, pharmacokinetics (PK) and activity data from the dose-escalation phase, 2-3 dose cohorts were expanded. Dose-limiting toxicity (DLT), maximum tolerated dose (MTD), recommended phase II dose (RP2D), efficacy, safety, tolerability, and pharmacokinetics (PK) were investigated.</p><p><strong>Results: </strong>A total of 29 patients with breast cancer (BC) (n = 14), sarcoma (n = 8), non-small cell lung cancer (n = 2) and others (n = 5) were enrolled. Neither DLT nor MTD were reached. All patients had at least one treatment-related adverse events (TRAEs), most of which were grade 1/2. Grade ≥ 3 TRAEs occurred in 51.7% of patients. One patient died from disease progression and five reported serious adverse events. Plasma concentrations increased dose-dependently, except at 600 mg, and steady state was reached at 2 weeks for 400 mg. One BC patient in the 600-mg cohort had a confirmed partial response. The disease control rate was 59.3% (95% CI, 38.8-77.6).</p><p><strong>Conclusion: </strong>SPH4336 demonstrated an acceptable safety profile and dose-dependent plasma exposure in patients with various advanced solid tumors. (ClinicalTrials.gov Identifier: NCT05905614; IRB Approved.).</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":"30 6","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12207880/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrasound-guided core needle biopsy of nodular lesions of the spleen in hematology clinical practice.","authors":"Alessandro Broccoli, Sofia Maria Bakken, Lisa Argnani, Camilla Mazzoni, Davide Di Benedetto, Marta Machado, Livia Masi, Nicola Venturoli, Daniela Agostinelli, Beatrice Casadei, Gabriele Gugliotta, Cinzia Pellegrini, Vittorio Stefoni, Carla Serra, Pier Luigi Zinzani","doi":"10.1093/oncolo/oyaf142","DOIUrl":"10.1093/oncolo/oyaf142","url":null,"abstract":"<p><strong>Background: </strong>Solid splenic lesions may be the expression of a lymphoproliferative disease spreading to the spleen or appear as the only manifestation of possible neoplastic diseases, mainly hematologic malignancies. Therefore, biopsy is of uttermost importance in clarifying their nature.</p><p><strong>Patients and methods: </strong>Forty-four patients with splenic nodular lesions suspected of hematologic disease underwent spleen contrast-enhanced ultrasonography and contextual biopsy using an 18-gauge needle. All procedures were performed on an outpatient basis. Patients with inconclusive findings or with a diagnosis of unaffected splenic tissue were followed up to discriminate between true and false-negative results.</p><p><strong>Results: </strong>All procedures ended up with sampling of splenic tissue without severe complications requiring hospitalization or supportive countermeasures. None was interrupted because of adverse event (AE)s. Out of 44 samples, a final diagnosis was accomplished in 39 cases, with a diagnostic yield of 88.6%. A diagnosis of lymphoma was made in 22 cases. Other diagnoses included: splenic metastases and splenic sarcoma (3 cases each), non-neoplastic lesions (3 cases), and unaffected splenic tissue (8 cases). Among the latter 8 patients, 1 received a diagnosis of Hodgkin lymphoma by marrow biopsy. All the other 7 patients never received a diagnosis of neoplasm and were true negative. Among the 5 patients with insufficient sampling, 3 were never diagnosed with a neoplasm during follow-up; 1 had myelofibrosis and 1 angiosarcoma. The sensitivity of the procedure was 96.6%; specificity was 100% and accuracy was 86.4%.</p><p><strong>Conclusions: </strong>Ultrasound-guided core needle biopsy of splenic nodular lesions can be safely performed on an outpatient basis with no severe AEs.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":"30 6","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149090/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144259333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary: is trogocytosis relevant for chimeric antigen receptor-T cells?","authors":"Bahareh Toolabi, Sidney W Whiteheart, Reinhold Munker","doi":"10.1093/oncolo/oyaf150","DOIUrl":"10.1093/oncolo/oyaf150","url":null,"abstract":"","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":"30 6","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12160798/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase II, multicenter, single-arm study of pemigatinib in patients with metastatic or unresectable colorectal cancer harboring FGFR alterations.","authors":"Margaret C Wheless, Tyler J Zemla, Joleen M Hubbard, John H Strickler, Olumide B Gbolahan, Luke Wilson, Blake Waechter, Fang-Shu Ou, Andrew B Nixon, Tanios S Bekaii-Saab, Kristen K Ciombor","doi":"10.1093/oncolo/oyaf069","DOIUrl":"10.1093/oncolo/oyaf069","url":null,"abstract":"<p><strong>Background: </strong>FGFR alterations are known to be driver alterations in several tumor types. We aimed to assess the efficacy of pemigatinib, an oral FGFR1-3 inhibitor, in patients with metastatic or unresectable colorectal cancer whose tumors harbored FGF/FGFR alterations.</p><p><strong>Patients and methods: </strong>The ACCRU-GI-1701 is a single-arm phase II trial which enrolled patients with previously treated FGF/FGFR-altered metastatic colorectal cancer to receive oral pemigatinib daily in 21-day cycles. The primary endpoint is objective response. Secondary endpoints include clinical benefit, progression-free survival, overall survival, quality of life, and adverse events (AEs). This trial was registered with ClinicalTrials.gov (NCT04096417).</p><p><strong>Results: </strong>Of the 14 patients included in the interim analysis, the objective response rate as well as clinical benefit rate were 0%. Given these results, the trial closed to enrollment after stage one due to futility. A total of 42.9% of patients had at least one grade 3 or higher AE, the most common being anemia and fatigue.</p><p><strong>Conclusion: </strong>Pemigatinib monotherapy did not lead to objective responses in patients with chemorefractory metastatic colorectal cancer harboring FGF/FGFR alterations, although it was overall relatively well tolerated with no new safety signals. Notably, 93% (n = 13) of patients had only FGF/FGFR mutations and amplifications; one patient had an FGFR3-WHSC1 fusion at a low cfDNA percentage (0.02%).</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":"30 6","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12166116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world treatment patterns and outcomes of patients with hormone receptor-positive/HER2-low metastatic breast cancer treated with chemotherapy.","authors":"Sandhya Mehta, Jackie Kwong, Clara Lam, Bruce Feinberg","doi":"10.1093/oncolo/oyaf106","DOIUrl":"10.1093/oncolo/oyaf106","url":null,"abstract":"<p><strong>Introduction: </strong>Hormonal therapy (HT) based regimen is the preferred first-line (1L) treatment for hormone receptor-positive (HR+) metastatic breast cancer (mBC) with human receptor epidermal growth factor 2 (HER2)-low expression. However, HT resistance frequently emerges with many receiving subsequent chemotherapy (CT). This study aimed to examine CT treatment patterns and outcomes among patients with HR+/HER2-low mBC.</p><p><strong>Patients and methods: </strong>Patient characteristics and clinical data of adults receiving CT for HR+/HER2-low mBC were collected via physician-abstracted chart review from 10/1/2021 to 1/31/2022. Data were summarized using descriptive statistics with the Kaplan-Meier method to estimate time-to-event outcomes. Statistical comparisons were conducted between patients who received 1L CT vs CT after HT-based regimens (any line).</p><p><strong>Results: </strong>Two hundred and twenty three HR+/HER2-low patients were included, and CT utilization was described by line within metastatic setting: 1L = 20.2% (n = 45), 2L 26.4% (n = 59), 3L+ = 53.4% (n = 119). A higher rate of visceral metastases (86.7% vs 65.7%, P = .01) and lower Eastern Cooperative Oncology Group (ECOG) score (88.9% vs 70.2%, P = 0.01) were associated with 1L CT vs CT post-HT-based treatment. The median time-to-treatment discontinuation (TTD) and real-world progression free survival (rwPFS) of CT were similar between the groups (TTD: 6.7 months vs 8.3 months for the 1L CT and CT post-HT-based regimen groups, respectively, P = .13; rwPFS: 9.3 months vs 8.8 months, P = .26).</p><p><strong>Conclusion: </strong>In this sample of HR+/HER2-low mBC patients, most patients switched to CT after two lines of therapy with a median rwPFS shorter than 10 months. The findings highlight unmet needs for a more effective targeted therapeutic alternative to CT for HR+/HER2-low mBC patients.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":"30 6","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12200229/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144318738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer.","authors":"Alexis LeVee, Esther Peluso, Melissa G Lechner, Nora Ruel, Joanne Mortimer, Irene Kang, Karen Tsai","doi":"10.1093/oncolo/oyaf134","DOIUrl":"10.1093/oncolo/oyaf134","url":null,"abstract":"<p><strong>Background: </strong>Emerging studies demonstrate that some bone-modifying agents (BMAs), such as denosumab (Dmab), can modulate immune responses by increasing tumor-infiltrating T cells and expanding the T-cell repertoire. Female patients with breast cancer in particular often receive concurrent treatment with immune checkpoint inhibitors (ICI) and BMAs. However, the clinical impact of BMAs on immune-related adverse events (irAE) and cancer outcomes in patients treated with ICI remains poorly understood.</p><p><strong>Materials and methods: </strong>Female patients with breast cancer treated with pembrolizumab between 2017 and 2024 were included. Patients were categorized according to BMA received: zoledronic acid (ZA), Dmab, or none. BMA therapy was considered received within a dose interval prior to ICI (12 months for ZA; 6 months for Dmab), during ICI therapy, or within 1 month of the last ICI dose.</p><p><strong>Results: </strong>In a cohort of 425 female patients with breast cancer treated with pembrolizumab, 55 (12.9%) received Dmab, 31 (7.3%) received ZA, and 339 (80.0%) received no BMA. A total of 255 (60%) patients had early-stage breast cancer, and 170 (40%) had metastatic disease. After a median follow-up of 19.4 months (95% CI, 17.5-20.8), the incidence of severe irAE was higher in patients who received Dmab vs those who received no BMA (21.8% vs 11.5%, P = .04). Patients who received Dmab had higher responses (48.0%) compared to those who received ZA (31.6%) and no BMA (35.0%), although not statistically significant (P = .3).</p><p><strong>Conclusion: </strong>This is the first study to suggest an increased rate of severe irAE and potential synergistic anti-tumor effect of Dmab in combination with ICI in female patients with breast cancer.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":"30 6","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12205979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma.","authors":"Kathryn E Beckermann, Neil J Shah, Matthew T Campbell, Naomi B Haas, Ariel Nelson, Moshe C Ornstein, Shifeng Mao, Holavanahalli S Keshava-Prasad, Hans Hammers, Xin Gao, Theodore Gourdin, Saby George, Christopher J Hoimes, Arif Hussain, Eric Jonasch, Brian I Rini, Martin H Voss","doi":"10.1093/oncolo/oyaf138","DOIUrl":"10.1093/oncolo/oyaf138","url":null,"abstract":"<p><strong>Background: </strong>Anexelokto (AXL) protein and its ligand, growth arrest specific-6 (GAS6), are important drivers of metastasis in patients with advanced clear cell renal cell carcinoma (ccRCC). Batiraxcept competitively binds GAS6 limiting interaction with AXL and thereby reduces downstream signaling. We present the safety and efficacy of batiraxcept alone and in combination with cabozantinib with or without nivolumab in patients with advanced ccRCC.</p><p><strong>Patients and methods: </strong>Phase 1b tested batiraxcept (15 and 20 mg/kg) plus cabozantinib (60 mg, N = 26) to identify the recommended phase 2 dose (RP2D) and evaluate safety. Phase 2 tested the batiraxcept RP2D as monotherapy (N = 10), as doublet therapy with cabozantinib (60 mg, N = 25) in previously treated patients, and as triplet therapy with cabozantinib (40 mg) and nivolumab (240 or 480 mg) in treatment-naïve patients (N = 11), with objective response rate (ORR) as the primary endpoint.</p><p><strong>Results: </strong>During the phase 1b (N = 26) study portion, no dose-limiting treatment-related adverse events (trAEs) were noted and batiraxcept 15 mg/kg plus cabozantinib 60mg was selected as the RP2D. The ORR across all doublet patients (phase 1 and 2, n = 51) was 43%, with median PFS of 9.2 months and grade ³3 trAEs in 73% of patients. Common batiraxcept trAEs were diarrhea (31%), fatigue (31%), and infusion reactions (24%). No new safety signals were noted among the triplet or monotherapy arms, which demonstrated 54% and 0% ORR, respectively.</p><p><strong>Conclusion: </strong>Batiraxcept was well tolerated with promising early efficacy signal when combined with cabozantinib, especially in heavily pretreated patients with ccRCC. The trial was discontinued early due to the sponsor's internal decision.</p><p><strong>Clinicaltrials.gov identifier: </strong>NCT04300140.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":"30 6","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12205982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}